XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, randomised interventional study registered as NCT06936527 by NovaOnco Therapeutics Co., Ltd., with a registry enrolment figure of 102 participants, started 2025-05-23 and due to reach its primary completion in 2028-04-30. Interventions recorded: Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI; Drug: XS-03; Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI. Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation. Primary outcome: Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 2: . Colorectal eligibility wording from the registry: "Patients with histologically and/or cytologically confirmed metastatic colorectal cancer who are not suitable for surgical treatment". Sites: China. No results are recorded here; the registry entry is the source.